便携低场磁共振在重症患者床旁脑损伤评估中的应用
这项前瞻性单中心队列研究在重症监护室使用便携低场MRI设备对50例危重患者进行床旁脑成像,评估脑损伤。结果显示,非COVID-19患者中97%(29/30)检出神经影像学异常,COVID-19伴意识改变患者中40%(8/20)存在异常,且无不良事件,表明床旁低场MRI在重症环境中可行。
要点
- 便携低场MRI可在ICU床旁完成T1、T2、FLAIR和DWI序列成像。
- 非COVID-19危重脑损伤患者中97%检出影像学异常。
- COVID-19伴意识改变患者中40%存在影像学异常。
核心结论
- 在重症监护环境中,使用便携低场MRI设备进行床旁脑成像具有可行性。
- 便携低场MRI有望在复杂临床环境中获取神经影像,辅助监测脑损伤。
研究设计与样本
- 纳入标准为存在神经损伤或意识改变、无常规MRI禁忌证、体型不超过扫描仪30 cm垂直开口。
- 在ICU房间内使用便携低场MRI设备进行床旁检查。
主要发现
- 50例患者中女性16例(32%),平均(SD)年龄59(12)岁(范围20-89岁)。
- 患者包括缺血性卒中9例、出血性卒中12例、蛛网膜下腔出血2例、创伤性脑损伤3例、脑肿瘤4例、COVID-19伴意识改变20例。
- 检查在ICU入院后中位5天(范围0-37天)进行。
- 分别有37、48、45、32例患者获得诊断级T1加权、T2加权、T2 FLAIR和DWI序列。
- 非COVID-19患者中29/30(97%)检出神经影像学异常,COVID-19患者中8/20(40%)存在异常。
临床怎么用
- 对于ICU中无法转运至常规MRI的危重脑损伤患者,可考虑使用便携低场MRI进行床旁脑成像评估。
- 便携低场MRI可用于监测神经损伤的发生和进展,尤其在神经科学或COVID-19 ICU环境中。
局限性
- 本研究为单中心、小样本(50例)队列研究,结果需在多中心更大样本中验证。
- 便携低场MRI的成像质量与常规高场MRI的对比未在本摘要中报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neuroimaging is a key step in the clinical evaluation of brain injury. Conventional magnetic resonance imaging (MRI) systems operate at high-strength magnetic fields (1.5-3 T) that require strict, access-controlled environments. Limited access to timely neuroimaging remains a key structural barrier to effectively monitor the occurrence and progression of neurological injury in intensive care settings. Recent advances in low-field MRI technology have allowed for the acquisition of clinically meaningful imaging outside of radiology suites and in the presence of ferromagnetic materials at the bedside. OBJECTIVE: To perform an assessment of brain injury in critically ill patients in intensive care unit settings, using a portable, low-field MRI device at the bedside. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, single-center cohort study of 50 patients admitted to the neuroscience or coronavirus disease 2019 (COVID-19) intensive care units at Yale New Haven Hospital in New Haven, Connecticut, from October 30, 2019, to May 20, 2020. Patients were eligible if they presented with neurological injury or alteration, no contraindications for conventional MRI, and a body habitus not exceeding the scanner's 30-cm vertical opening. Diagnosis of COVID-19 was determined by positive severe acute respiratory syndrome coronavirus 2 polymerase chain reaction nasopharyngeal swab result. EXPOSURES: Portable MRI in an intensive care unit room. MAIN OUTCOMES AND MEASURES: Demographic, clinical, radiological, and treatment data were collected and analyzed. Brain imaging findings are described. RESULTS: Point-of-care MRI examinations were performed on 50 patients (16 women [32%]; mean [SD] age, 59 [12] years [range, 20-89 years]). Patients presented with ischemic stroke (n = 9), hemorrhagic stroke (n = 12), subarachnoid hemorrhage (n = 2), traumatic brain injury (n = 3), brain tumor (n = 4), and COVID-19 with altered mental status (n = 20). Examinations were acquired at a median of 5 (range, 0-37) days after intensive care unit admission. Diagnostic-grade T1-weighted, T2-weighted, T2 fluid-attenuated inversion recovery, and diffusion-weighted imaging sequences were obtained for 37, 48, 45, and 32 patients, respectively. Neuroimaging findings were detected in 29 of 30 patients who did not have COVID-19 (97%), and 8 of 20 patients with COVID-19 (40%) demonstrated abnormalities. There were no adverse events or complications during deployment of the portable MRI or scanning in an intensive care unit room. CONCLUSIONS AND RELEVANCE: This single-center series of patients with critical illness in an intensive care setting demonstrated the feasibility of low-field, portable MRI. These findings demonstrate the potential role of portable MRI to obtain neuroimaging in complex clinical care settings.
引用
- Sheth KN, Mazurek MH, Yuen MM, et al. Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. JAMA Neurol. 2020. PMID: 32897296. doi:10.1001/jamaneurol.2020.3263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。